Lundgrens assisted FC Capital in its investment in Acesion Pharma
FC Capital is a life science focused private equity fund based in China and the US that specializes in global innovative medical and healthcare investments.
Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
Co-equity investors in Acesion Pharma are Novo A/S, Broadview Ventures, SEED Capital and Wellcome Trust.
The core team from Lundgrens was Thomas Kræmer and Frederikke Lindbo Hennings.